Isis Pharmaceuticals’ License Agreement with Bayer for ISIS-FXI Rx Receives Hart-Scott-Rodino Approval

ByConnor Hodde

Isis Pharmaceuticals, Inc. (ISIS) today announced that its license agreement with Bayer HealthCare (Bayer) to develop and commercialize ISIS-FXIRx has received clearance under the Hart-Scott-Rodino Antitrust Improvements Act.  After completion of ongoing activities at Isis, Bayer will assume all global clinical development as well as worldwide regulatory and commercialization responsibilities for ISIS-FXIRx.  ISIS-FXIRx is an antisense drug in development for the prevention of clotting disorders.

Read the entire article here.

Similar Posts

eyecro COO Dr. Rafal Farjo to Chair Upcoming Conference

ByConnor Hodde

The 6th Ocular Diseases & Drug Discovery Conference is taking place on March 20-21, 2014 in San Diego, CA. The conference continues to offer presentations on novel and innovative therapeutics in ocular drug development and discovery. This forum allows for excellent networking, the exchange of ideas, and sharing of challenges; all with a united common…

Magnetic stimulation as retinal treatment

ByConnor Hodde

Brainsway Ltd. has announced interim results from an animal study being conducted at the Sheba Medical Center to explore the effects of the company’s transcranial magnetic stimulation device on age-related macular degeneration. A short-lasting improvement in the retina’s response to light was observed following this stage of the study, with the rats who received the magnetic…

Interim results from clinical trial demonstrate safety of cell-based therapy for retinitis pigmentosa

ByConnor Hodde

Regenerative medicine company jCyte and the Sue & Bill Gross Stem Cell Research Center at the University of California, Irvine report that their investigational therapy for retinitis pigmentosa (RP) has demonstrated a favorable safety and tolerability profile in an ongoing Phase I/II clinical trial.  The cell-based approach taken is intended to rescue sick and dying…

EyeCRO and MPI Research Partner to Develop New Preclinical Models of Ophthalmic Disease

ByConnor Hodde

Oklahoma City, OK; Ann Arbor, MI; and Mattawan, MI (PRWEB) May 01, 2017 eyecro and MPI Research, two global leaders in preclinical ophthalmology contract research, today announced a collaboration to develop and commercialize large mammalian preclinical models for various ophthalmic diseases, including Age-Related Macular Degeneration and Diabetic Retinopathy. The partnership leverages the unique skills and…

Kala Pharmaceuticals Announces Positive Results from Phase 2 Trial of KPI-121 in Dry Eye Disease

ByConnor Hodde

Kala Pharmaceuticals, Inc. (Kala), a developer of innovative ophthalmic products based on its proprietary mucus-penetrating particle (MPP) technology, today announced positive top-line results from a Phase 2 clinical trial of KPI-121.  KPI-121 achieved statistical significance for the primary sign endpoint of bulbar conjunctival hyperemia, and promising trends were observed for key symptom endpoints. “The achievement of…

SOCS3 in retinal neurons and glial cells suppresses VEGF signaling to prevent pathological neovascular growth

ByConnor Hodde

Neurons and glial cells in the retina contribute to neovascularization, or the formation of abnormal new blood vessels, in proliferative retinopathy, a condition that can lead to vision loss or blindness. We identified a mechanism by which suppressor of cytokine signaling 3 (SOCS3) in neurons and glial cells prevents neovascularization. We found that Socs3 expression…